Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. (Q52526726)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 1997

Language	Label	Description	Also known as
English	Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.	scientific article published in June 1997

Statements

scholarly article

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. (English)

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

1 reference

based on heuristic

inferred from title

Nungavarm S. Ramamurthy

4

object named as

N S Ramamurthy

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

author name string

W Pruzanski

1

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

E Stefanski

2

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

P Vadas

3

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

language of work or name

0 references

publication date

1 June 1997

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

Biochemical Pharmacology

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

53

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

12

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

1901-1907

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Current management of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Inflammatory effect of intradermal administration of soluble phospholipase A2 in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Purification and characterization of a phospholipase A2 from human ileal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Initiation of anastomotic recurrence of Crohn's disease after ileocolic resection. Onset proximal to the junction and preceded by increased phospholipase A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Interleukin-1 beta, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Insulin-like growth factors counteract the effect of interleukin 1β on type II phospholipase A2 expression and arachidonic acid release by rabbit articular chondrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Induction of circulating group II phospholipase A2 expression in adults with malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Identifiers

10.1016/S0006-2952(97)00137-8

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

release_gi5qaekd7jeezkp4hysir2ilsu

1 reference

https://api.fatcat.wiki/v0/release/gi5qaekd7jeezkp4hysir2ilsu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

2 May 2018

http://europepmc.org/abstract/MED/9256165

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52526726&oldid=1844221815"